Comparative Pharmacology
Head-to-head clinical analysis: SULFADIAZINE versus SULTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFADIAZINE versus SULTRIN.
SULFADIAZINE vs SULTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking the synthesis of folic acid in bacteria.
Sultrin (sulfanilamide, sulfathiazole, sulfacetamide) is a triple sulfonamide combination that acts as a bacteriostatic agent. It inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking the conversion of PABA to dihydrofolic acid. This disrupts nucleic acid synthesis in susceptible bacteria.
Oral: 2-4 g initially, then 1 g every 4-6 hours for mild to moderate infections; for severe infections, 4 g initially followed by 1.5 g every 4 hours. IV: Not available in IV form in the US; if using oral suspension, adjust accordingly.
Intravaginal administration: one applicatorful (approximately 5 g) of Sultrin Triple Sulfa Cream (containing sulfathiazole, sulfacetamide, and sulfabenzamide) intravaginally once or twice daily for 4 to 7 days. Oral: Not applicable.
None Documented
None Documented
Clinical Note
moderateSulfadiazine + Gatifloxacin
"Sulfadiazine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfadiazine + Rosoxacin
"Sulfadiazine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfadiazine + Levofloxacin
"Sulfadiazine may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSulfadiazine + Trovafloxacin
"Sulfadiazine may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life 10-20 hours (prolonged in renal impairment; may require dose adjustment)
Terminal half-life 8-12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min)
Renal excretion of unchanged drug (50-70%) and acetylated metabolites; minor biliary/fecal (<5%)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic